At a glance
ClinicalIndex Comparison RecordPhase 1Completed· 80 enrolled
Drug / intervention
BI 3006337 +1 moredrug
Likely dose
Not stated in record
Structured eligibility isn't available for this trial yet — see the full criteria in the Eligibility tab below.
Standardized by ClinicalIndex from the ClinicalTrials.gov record · verify against the source.
Safety, Tolerability, Pharmacokinetics and Pharmacodynamics of Single Rising Subcutaneous Doses of BI 3006337 in Healthy Male Subjects (Single-blind, Partially Randomised Within Dose Groups, Placebo-controlled, Parallel (Sequential) Group Design)
In Brief
A Phase 1 clinical trial evaluating BI 3006337 and Placebo for Healthy. Completed, enrolled 80 participants across 2 sites in 2 countries.
Detailed Summary
The main objectives of this trial are to investigate safety, tolerability and pharmacokinetics of BI 3006337 in healthy male subjects following subcutaneous administration of single-rising doses.
Study Details
Study Typeinterventional
Allocation--
Masking--
Primary Purpose--
ConditionsHealthy
CountriesBelgium, Netherlands
Collaborators--
Timeline
Phase 1CompletedFinished
20222023202420252026
First PostedOct 2021
Enrollment StartOct 2021
Primary CompletionMar 2023
TodayJul 2026
First PostedOct 13, 2021
Enrollment StartOct 18, 2021
Primary CompletionMar 3, 2023
TodayJul 2, 2026
Enrollment to primary: 1.4 yearsPosted 4.7 years ago
Interventions
BI 3006337drug
BI 3006337
Placebodrug
Placebo